Month: July 2023

New York/Malmö, July 28, 2023 (GLOBE NEWSWIRE) — byNordic Acquisition Corporation (NASDAQ: BYNO) (the “Company”) today announced several actions being undertaken in anticipation of the previously announced special meeting of stockholders of the Company to be held at 10:00 a.m. Eastern Time on August 8, 2023 (the “Special Meeting”) for the purpose of considering and voting on, among other proposals, a proposal to extend (the “Extension”) the date (the “Original Termination Date”) by which the Company must consummate an initial business combination  from August 11, 2023 to February 12, 2024  (the “Initial Extended Date”) or such earlier date as determined by the Company’s board of directors (the “Board”), in its sole discretion, and to allow the Company by resolution of the Board without another stockholder vote, to elect to extend...

BURR RIDGE, Ill., July 28, 2023 (GLOBE NEWSWIRE) — BankFinancial Corporation (Nasdaq – BFIN) (the “BankFinancial”) filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, and a Quarterly Financial and Statistical Supplement in Form 8-K with the U.S. Securities and Exchange Commission (the “SEC”) today. BankFinancial reported net income for the three months ended June 30, 2023, of $2.3 million, or $0.18 per common share, compared to net income of $2.6 million, or $0.19 per common share, for the three months ended June 30, 2022. At June 30, 2023, BankFinancial had total assets of $1.527 billion, total loans of $1.171 billion, total deposits of $1.304 billion and stockholders’ equity of $152 million. The Quarterly Report on Form 10-Q and the Quarterly Financial and Statistical Supplement will be available...

Vancouver, BC, July 28, 2023 (GLOBE NEWSWIRE) — RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) (the “Company”) today announced the resignation of Steve Marshall, Chief Executive Officer, due to health reasons. The Board has reviewed comprehensive medical history dating back to November 2022, demonstrating continuous inquiries into a pulmonary pathology associated with suspected chronic obstructive pulmonary disease alleviated by doctor-prescribed Symbicort. Despite mandated vaccinations and correctly administered boosters, Mr. Marshall suffered three particularly aggressive bouts of COVID-19 between January 2020 and July 2022. Due to the recent worsening of symptoms, physicians have not ruled out Long COVID. Under a consensus medical recommendation, the latest medical reports show that Mr....

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that it received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying OKYO that, for the previous 30 consecutive business days, the market value of OKYO’s ordinary shares had closed below the minimum $35 million requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “Market Value Rule”). The Nasdaq deficiency letter has no immediate effect on...